Rubedo Life Sciences Announces European Expansion Ahead of First Clinical Trial

Contributed by: Business Wire

Logo

Business Wire logo

Images

Marco Quarta (right), Rubedo Life Sciences CEO and Co-Founder, notarizes the incorporation of Rubedo's European Headquarters in Milan (Photo: Business Wire)
Marco Quarta (right), Rubedo Life Sciences CEO and Co-Founder, notarizes the incorporation of Rubedo's European Headquarters in Milan (Photo: Business Wire)
Business Wire embedded0

Tags

Science
Biotechnology
Research
Pharmaceutical
General Health
Health
Genetics
Clinical Trials
European Expansion

More Like This

Rubedo Life Sciences scientists. Photo credit: ALESSANDRO GANDOLFI

Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital

Rubedo Life Sciences scientists (Photo: Business Wire)

Rubedo Life Sciences and Beiersdorf Announce Multi-Year Partnership to Pioneer New Skin Care Products that Address Cellular Aging

Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

Business Wire logo

Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress

Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023